1: Keuroghlian AS, Gunderson JG, Pagano ME, Markowitz JC, Ansell EB, Shea MT, Morey LC, Sanislow C, Grilo CM, Stout RL, Zanarini MC, McGlashan TH, Skodol AE. Interactions of borderline personality disorder and anxiety disorders over 10 years. J Clin Psychiatry. 2015 Nov;76(11):1529-34. doi: 10.4088/JCP.14m09748. PubMed PMID: 26114336.
2: Patel NC, Palmer WC, Gill KR, Cangemi D, Diehl N, Stark ME. Changes in efficiency and resource utilization after increasing experience with double balloon enteroscopy. World J Gastrointest Endosc. 2013 Mar 16;5(3):89-94. doi: 10.4253/wjge.v5.i3.89. PubMed PMID: 23515876; PubMed Central PMCID: PMC3600554.
3: Whitney DW. Guide to preemption of state-law claims against Class III PMA medical devices. Food Drug Law J. 2010;65(1):113-39, ii-iii. PubMed PMID: 24475536.
4: Amano T, Aihua Z, Matsubayashi H, Seki T, Serikawa T, Sasa M, Sakai N. Antiepileptic effects of single and repeated oral administrations of S-312-d, a novel calcium channel antagonist, on tonic convulsions in spontaneously epileptic rats. J Pharmacol Sci. 2004 Jul;95(3):355-62. PubMed PMID: 15272212.
5: Yagami T, Ueda K, Sakaeda T, Itoh N, Sakaguchi G, Okamura N, Hori Y, Fujimoto M. Protective effects of a selective L-type voltage-sensitive calcium channel blocker, S-312-d, on neuronal cell death. Biochem Pharmacol. 2004 Mar 15;67(6):1153-65. PubMed PMID: 15006551.
6: Tanaka H, Mizojiri K. Drug-protein binding and blood-brain barrier permeability. J Pharmacol Exp Ther. 1999 Mar;288(3):912-8. PubMed PMID: 10027826.
7: Takamatsu H, Kondo K, Ikeda Y, Umemura K. Neuroprotective effects depend on the model of focal ischemia following middle cerebral artery occlusion. Eur J Pharmacol. 1998 Dec 4;362(2-3):137-42. PubMed PMID: 9874163.
8: Eigyo M, Shiomi T, Inoue Y, Sakaguchi I, Ishibashi C, Murata S, Koyabu K, Matsushita A, Adachi I, Ueda M. Pharmacological studies on a new dihydrothienopyridine calcium antagonist, S-312-d. 5th communication: anticonvulsant effects in mice. Jpn J Pharmacol. 1994 Jun;65(2):175-7. PubMed PMID: 7967231.
9: Yasui M, Kawasaki K. Vulnerability of CA1 neurons in SHRSP hippocampal slices to ischemia, and its protection by Ca2+ channel blockers. Brain Res. 1994 Apr 11;642(1-2):146-52. PubMed PMID: 8032875.
10: Ueda M, Masui M, Kawakami M, Matsunaga K, Gemba T, Ninomiya M, Nakano A, Torii M, Adachi I, Ito H. Pharmacological studies on a new dihydrothienopyridine calcium antagonist. 4th communication: prophylactic and therapeutic effects of S-(+)-methyl-4,7-dihydro-3-isobutyl-6-methyl-4-(3-nitrophenyl)thieno[2, 3- b]pyridine-5-carboxylate in stroke-prone spontaneously hypertensive rats. Arzneimittelforschung. 1993 Dec;43(12):1291-303. PubMed PMID: 8141816.
11: Ueda M, Matsumura S, Masui M, Matsuura E, Kawakami M, Fujitomo H, Umeda T, Kagawa H, Hirohata S, Shima K, et al. Pharmacological studies on a new dihydrothienopyridine calcium antagonist. 3rd communication: antihypertensive effects of S-(+)-methyl-4,7-dihydro-3-isobutyl-6-methyl-4-(3-nitrophenyl)thieno[2, 3-b] pyridine-5-carboxylate in hypertensive rats and dogs. Arzneimittelforschung. 1993 Dec;43(12):1282-90. PubMed PMID: 8141815.
12: Nakajima M, Adachi I, Ueda M. Pharmacological studies on a new Dihydrothienopyridine calcium antagonist. 2nd communication: effects of S-(+)-methyl-4,7-dihydro-3-isobutyl-6-methyl-4- (3-nitrophenyl)thieno[2,3-b]pyridine-5-carboxylate on the 1,4-dihydropyridine binding sites in the brain and on isolated arteries in the Cynomolgus monkey. Arzneimittelforschung. 1993 Dec;43(12):1276-82. PubMed PMID: 8141814.
13: Ueda M, Matsumura S, Masui M, Matsuura E, Uno O, Kawakami M, Ninomiya M, Adachi I. Pharmacological studies on a new dihydrothienopyridine calcium antagonist. 1st communication: comparative studies on the cardiovascular effects of methyl-4,7-dihydro-3-isobutyl-6-methyl-4-(3-nitrophenyl)thieno[2,3- b]pyridine-5-carboxylate and its two enantiomers in experimental animals. Arzneimittelforschung. 1993 Dec;43(12):1270-5. PubMed PMID: 8141813.
14: Jizomoto H, Kanaoka E, Sugita K, Hirano K. Gelatin-acacia microcapsules for trapping micro oil droplets containing lipophilic drugs and ready disintegration in the gastrointestinal tract. Pharm Res. 1993 Aug;10(8):1115-22. PubMed PMID: 8415395.
15: Gemba T, Ninomiya M, Matsunaga K, Ueda M. Effects of a novel calcium antagonist, S-(+)-methyl-4,7-dihydro-3-isobutyl-6- methyl-4-(3-nitrophenyl)thieno[2,3-b]pyridine-5-carboxylate (S-312-d), on ischemic amino acid release and neuronal injury in stroke-prone spontaneously hypertensive rats. J Pharmacol Exp Ther. 1993 Apr;265(1):463-7. PubMed PMID: 8474028.
16: Fujitomo H, Nishino I, Ueno K, Umeda T. Determination of the enantiomers of a new 1,4-dihydropyridine calcium antagonist in dog plasma by achiral/chiral coupled high-performance liquid chromatography with electrochemical detection. J Pharm Sci. 1993 Mar;82(3):319-22. Erratum in: J Pharm Sci 1993 Dec;82(12):1300. PubMed PMID: 8450429.
17: Dessy C, Salomone S, Morel N, Godfraind T. Activity of dihydrothienopyridine S312 enantiomers on L-type Ca2+ channels in isolated rat aorta and cerebral microvessels. Eur J Pharmacol. 1993 Feb 16;231(3):435-42. PubMed PMID: 8449235.
18: Nakano H, McCormick DB. Stereospecificity of the metal.ATP complex in flavokinase from rat small intestine. J Biol Chem. 1991 Nov 25;266(33):22125-8. PubMed PMID: 1657990.
19: Mihara S, Fujimoto M. Effect of S-312, a new calcium channel blocker, on the 1,4-dihydropyridine binding sites in porcine basilar blood vessels and rat aortic smooth muscle cells. Jpn J Pharmacol. 1991 Jul;56(3):249-59. PubMed PMID: 1832726.
20: Shimizu T, Kawabata T, Nakamura M. Protective effect of a novel calcium blocker, S-312-d, on ischemic acute renal failure in rat. J Pharmacol Exp Ther. 1990 Nov;255(2):484-90. PubMed PMID: 2243338.